CATALOGO DEI PRODOTTI DELLA RICERCA

MELISI, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.178
EU - Europa 7.165
AS - Asia 5.481
SA - Sud America 751
Continente sconosciuto - Info sul continente non disponibili 210
AF - Africa 153
OC - Oceania 17
Totale 22.955
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.871
RU - Federazione Russa 2.735
SG - Singapore 2.107
CN - Cina 1.785
GB - Regno Unito 1.242
IT - Italia 886
BR - Brasile 576
SE - Svezia 503
VN - Vietnam 490
HK - Hong Kong 464
DE - Germania 447
FR - Francia 366
IE - Irlanda 363
FI - Finlandia 251
KR - Corea 173
CA - Canada 160
BD - Bangladesh 87
UA - Ucraina 82
IN - India 69
NL - Olanda 64
AR - Argentina 60
JP - Giappone 49
TR - Turchia 43
MX - Messico 41
ZA - Sudafrica 38
NG - Nigeria 36
AT - Austria 35
PL - Polonia 34
ES - Italia 32
ID - Indonesia 31
EC - Ecuador 27
IQ - Iraq 24
VE - Venezuela 23
BE - Belgio 21
SA - Arabia Saudita 21
CL - Cile 18
PK - Pakistan 17
PY - Paraguay 17
TG - Togo 17
AU - Australia 16
CO - Colombia 16
CR - Costa Rica 16
BJ - Benin 15
CH - Svizzera 15
JO - Giordania 15
MA - Marocco 15
GT - Guatemala 13
PH - Filippine 13
PR - Porto Rico 13
UZ - Uzbekistan 13
CZ - Repubblica Ceca 11
LT - Lituania 11
PT - Portogallo 11
SV - El Salvador 11
JM - Giamaica 10
NI - Nicaragua 10
HN - Honduras 9
TT - Trinidad e Tobago 9
IL - Israele 8
IR - Iran 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
CW - ???statistics.table.value.countryCode.CW??? 7
DZ - Algeria 7
EE - Estonia 7
PE - Perù 7
KE - Kenya 6
NP - Nepal 6
AL - Albania 5
AZ - Azerbaigian 5
DK - Danimarca 5
KG - Kirghizistan 5
RO - Romania 5
UY - Uruguay 5
BG - Bulgaria 4
BY - Bielorussia 4
EG - Egitto 4
EU - Europa 4
GR - Grecia 4
HU - Ungheria 4
KZ - Kazakistan 4
LK - Sri Lanka 4
NO - Norvegia 4
PA - Panama 4
QA - Qatar 4
SN - Senegal 4
AM - Armenia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GP - Guadalupe 3
HR - Croazia 3
LB - Libano 3
BO - Bolivia 2
CI - Costa d'Avorio 2
HT - Haiti 2
KH - Cambogia 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
RS - Serbia 2
Totale 22.730
Salva come PNG Salva come JPEG
Città #
Ashburn 1.356
Singapore 1.090
Southend 1.016
Moscow 920
San Jose 897
Chandler 823
Dallas 658
Jacksonville 473
Hong Kong 461
Woodbridge 377
Dublin 361
Verona 307
Council Bluffs 286
Beijing 283
The Dalles 270
Ann Arbor 265
Ho Chi Minh City 178
Jinan 161
Houston 146
New York 138
Los Angeles 137
Lawrence 130
Princeton 130
Wilmington 128
Munich 121
Hanoi 98
Santa Clara 98
Shenyang 95
Nanjing 86
Helsinki 79
Tianjin 77
Buffalo 76
Hebei 66
São Paulo 65
Milan 58
Columbus 57
Redondo Beach 54
Changsha 53
Zhengzhou 46
Sindelfingen 45
Haikou 44
Chicago 43
Frankfurt am Main 43
Rome 43
Orem 42
Turku 41
Tokyo 40
Atlanta 39
London 39
Montreal 38
Hangzhou 37
Taiyuan 36
Guangzhou 35
Redwood City 35
Abuja 34
Toronto 34
Washington 34
Taizhou 31
Ningbo 30
Nanchang 29
Seattle 28
San Francisco 27
Johannesburg 26
Phoenix 26
Warsaw 26
Brooklyn 25
Denver 25
Fuzhou 25
Rio de Janeiro 25
Da Nang 23
Amsterdam 22
Boston 22
Nuremberg 22
Redmond 22
Boardman 21
Kent 21
Bologna 20
Brussels 20
Dong Ket 20
Jiaxing 20
Jakarta 19
Vienna 18
Brasília 17
Lomé 17
Norwalk 17
Bar Harbor 16
Barnet 16
Seoul 16
Belo Horizonte 15
Cotonou 15
Haiphong 15
Mexico City 15
North Bergen 15
Stockholm 15
Amman 14
Chennai 14
Dongguan 14
Mumbai 13
Naples 13
Zurich 13
Totale 13.685
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 325
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 304
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 275
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 268
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 267
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 246
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma 242
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 234
NF-κB as a target for pancreatic cancer therapy. 226
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 217
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 216
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma 214
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 212
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 211
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 207
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 205
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 204
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 203
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 202
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 200
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 200
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 199
Histogram analysis of magnetic resonance images: evaluation of intra-tumoral heterogeneity and correlation with pathological findings in solid pancreatic tumors. 198
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib 198
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 197
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 197
The development of PARP as a successful target for cancer therapy 196
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 195
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 194
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 193
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells 191
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 190
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 190
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results 187
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer 185
Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer 183
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study 182
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data 182
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 182
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 181
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 181
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 181
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 179
Pancreatic Cancer: between bench and bedside. 177
CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy 175
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 173
ESGAR 2018 Book of Abstracts 171
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 170
EMT and Treatment Resistance in Pancreatic Cancer 169
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 168
Angiogenesis: A target for cancer therapy. 163
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 163
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 163
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion 163
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 162
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 162
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma 161
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 160
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 160
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 160
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 156
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer 154
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. 154
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 152
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial 151
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 151
Toll-Like Receptor 9 Agonists for Cancer Therapy 151
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 150
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma 150
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 148
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer 147
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies 146
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 144
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 144
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports 143
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 142
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 142
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) 141
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 140
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 139
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) 138
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 136
Rare secondary tumors of the pancreas 135
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 134
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells 134
The curious case of Gαs gain-of-function in neoplasia 134
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer 133
Injectable Thermogelling Nanostructured Ink as Simultaneous Optical and Magnetic Resonance Imaging Contrast Agent for Image-Guided Surgery 133
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 133
The Multifaceted Role of TGF-β in Gastrointestinal Tumors 133
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. 132
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts 131
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 130
The novel poly(ADP-ribose) polymerase (PARP)-1 inhibitor, BSI-401, has anti tumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer 130
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells 130
Cooperative antitumor and antiangiogenic activity after oral administration of a novel taxane, an antisense targeting protein kinase A and the EGF receptor inhibitor Iressa 129
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 129
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 129
Permissive State of EMT: The Role of Immune Cell Compartment 129
Nrf2 Plays a Key Role in Erythropoiesis during Aging 128
Totale 17.444
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.303
article - articoli 71.953
book - libri 0
conference - conferenze 9.400
curatela - curatele 0
other - altro 559
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.391
Totale 166.606
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022674 0 0 0 161 15 15 9 61 38 22 67 286
2022/20232.272 177 230 217 350 205 546 27 135 289 23 47 26
2023/20241.309 43 101 91 122 162 182 115 154 15 70 197 57
2024/20253.197 165 188 109 505 137 98 175 158 487 199 310 666
2025/20269.106 680 428 677 1.405 2.252 611 884 484 731 563 172 219
2026/20271.850 116 320 375 1.039 0 0 0 0 0 0 0 0
Totale 22.955